Hong Kong'da farklı dopamin agonistleri ile tedavi edilen İdiyopatik Parkinson Hastalığı'nda impuls kontrolü ve ilgili davranış bozuklukları (ICRD): Herhangi bir dopamin agonisti daha iyi mi?

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

ObjectiveTo assess the incidence of Impulse control and related behavioral disorders (ICRD) in Chinese Idiopathic Parkinson Disease (IPD) patients treated with different dopamine agonists (DA), and their clinical characteristics and associated risk factors.MethodsThis was an observational cohort study based on clinical interviews and medical records of IPD patients treated with DA for >6 months in three hospitals in Hong Kong. The short version of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP-S) was used to screen for ICRD. ICRD incidence among different DA, clinical characteristics and risk factors were examined.ResultsIncidence of ICRD was analyzed in 311 patients taking their first, single DA. 43 patients (13.8 %) developed ICRD. The mean duration of IPD was 8.5 ± 5.6 years and median HY stage was 2.5. Bromocriptine and rotigotine users had lower ICRD incidence rate. Both pramipexole [adjusted HR 7.28 (2.46-21.54), p ConclusionBromocriptine and probably rotigotine carried a lower ICRD risk compared to pramipexole and ropinirole.

İlgili konular